Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review
Marco Allinovi, Jacopo Lomi, Matteo Accinno, Maxime Teisseyre, Michael Diomaiuti, Raffaele Madeo, Federica Allegretta, Andrea Matucci, Alessandra Vultaggio · 2026
Read Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review by Marco Allinovi, Jacopo Lomi, Matteo Accinno, Maxime Teisseyre, Michael Diomaiuti, Raffaele Madeo, Federica Allegretta, Andrea Matucci, Alessandra Vultaggio (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13620468.txt.
Description
Marco Allinovi and co-authors review a hidden snag in treatment with rituximab, a lab-made antibody used for kidney and immune diseases. Some patients build their own antibodies against the drug. The 2026 review sums up how often these blockers appear and what they do. Rates vary widely by disease, test method, and the timing of the test.
Where blockers show up, drug levels tend to run lower and B cells return sooner. Patients also remit less often, relapse more, and face more allergic reactions. Not every blocker matters in the clinic, the authors note. They urge better testing and care plans tuned to each patient.
Catalog record
| CREATOR | Marco Allinovi, Jacopo Lomi, Matteo Accinno, Maxime Teisseyre, Michael Diomaiuti, Raffaele Madeo, Federica Allegretta, Andrea Matucci, Alessandra Vultaggio |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |